ReviewNeurochemical research2021
Epilepsy Associated Depression: An Update on Current Scenario, Suggested Mechanisms, and Opportunities.
Review in Neurochemical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Prevalence and factors associated with depressive symptoms among patients with epilepsy in Ethiopia: a national-based systematic review and meta-analysis.Frontiers in neurology · 2024Pooled it
- Causal effect of psychiatric disorders on epilepsy: A two-sample Mendelian randomization study.Brain and behavior · 2023Pooled it
- Sodium valproate and gabapentin reduce the seizure-like behavior induced by pentylenetetrazol and mechanical stress in Drosophila melanogaster: sex influence on behavioral responses.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Mirtazapine revisited: new therapeutic perspectives and formulation advances.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Effect of perampanel in reducing depression in patients with focal epilepsy.IBRO neuroscience reports · 2025Article
- Risk factor analysis and establishment of a predictive model for epilepsy comorbid with depression.PloS one · 2025Article
- Kindling Models of Epileptogenesis for Developing Disease-Modifying Drugs for Epilepsy.Current protocols · 2024Article
- The association between epilepsy and sleep disturbance in US adults: the mediating effect of depression.BMC public health · 2024Article
- Is the regulation of lamotrigine on depression in patients with epilepsy related to cytokines?Heliyon · 2024Article
- [Saikosaponin a alleviates pentylenetetrazol-induced acute epileptic seizures in mouse models of depression by suppressing microglia activation-mediated inflammation].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- Hypothalamic-Pituitary-Adrenal Axis and Epilepsy.Journal of clinical neurology (Seoul, Korea) · 2024Review
- Risk analysis of depression among adult patients with epilepsy of different sex: a retrospective single-center study from China.Frontiers in psychiatry · 2023Article
- Ferulic acid inhibits catamenial epilepsy through modulation of female hormones.Metabolic brain disease · 2022Article
- Network pharmacological investigation into the mechanism of Kaixinsan powder for the treatment of depression.Metabolic brain disease · 2022Article
- Role of Short Chain Fatty Acids in Epilepsy and Potential Benefits of Probiotics and Prebiotics: Targeting "Health" of Epileptic Patients.Nutrients · 2022Review
- Kynurenine Metabolism and Alzheimer's Disease: The Potential Targets and Approaches.Neurochemical research · 2022Review
- Anticonvulsant Effect of Asparagus racemosus Willd. in a Mouse Model of Catamenial Epilepsy.Neurochemical research · 2022Article
- Comorbid epilepsy and depression-pharmacokinetic and pharmacodynamic drug interactions.Frontiers in pharmacology · 2022Review
- Impact of Stress on Epilepsy: Focus on Neuroinflammation-A Mini Review.International journal of molecular sciences · 2021Review
- Microbiota-Gut-Brain Axis and Epilepsy: A Review on Mechanisms and Potential Therapeutics.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression is one of the most frequent psychiatric comorbidities associated with epilepsy having a major impact on the patient's quality of life. Several screening tools are available to identify and follow up psychiatric disorders in epilepsy. Out of various psychiatric disorders, people with epilepsy (PWE) are at greater risk of developing depression. This bidirectional relationship further hinders pharmacotherapy of comorbid depression in PWE as some antiepileptic drugs (AEDs) worsen associated depression and coadministration of existing antidepressants (ADs) to alleviate comorbid depression has been reported to worsen seizures. Selective serotonin reuptake inhibitors (SSRIs) and selective serotonin and norepinephrine reuptake inhibitors (SNRIs) are first choice of ADs and are considered safe in PWE, but there are no high-quality evidences. Similar to observations in people with depression, PWE also showed pharmacoresistant to available SSRI/SNRIs, which further complicates the disease prognosis. Randomized double-blind placebo-controlled clinical trials are necessary to report efficacy and safety of available ADs in PWE. We should also move beyond ADs, and therefore, we reviewed common pathological mechanisms such as neuroinflammation, dysregulated hypothalamus pituitary adrenal (HPA) axis, altered neurogenesis, and altered tryptophan metabolism responsible for coexistent relationship of epilepsy and depression. Based on these common pertinent pathways involved in the genesis of epilepsy and depression, we suggested novel targets and therapeutic approaches for safe management of comorbid depression in epilepsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.